CorMedix (CRMD) Cash from Operations (2010 - 2025)
CorMedix (CRMD) posted Cash from Operations of 94461181.0 for Q4 2025, up 206.13% sequentially from 30856502.0 in Q3 2025, and up 1782.34% YoY from 5018296.22 in Q4 2024.
CorMedix (CRMD) Cash from Operations (2010 - 2025) Analysis & Trends
CorMedix has reported Cash from Operations for 15 years, with the latest figure at 94461181.0 in Q4 2025.
- Quarterly Cash from Operations rose 1782.34% year-over-year to 94461181.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 175046000.0 (up 445.84% YoY) and the FY2025 annual result came in at 175046000.0, up 445.84% from the prior year.
- Cash from Operations advanced to 94461181.0 in Q4 2025 per CRMD's latest filing, from 30856502.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 94461181.0 in Q4 2025 and troughed at 17310294.0 in Q1 2024.
- A 5-year average of 2025478.25 and a median of 6075137.5 in 2022 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2021 and 2025: Cash from Operations sank 309.81% in 2021, then jumped 1782.34% in 2025.
- Over 5 years, Cash from Operations stood at 5869360.0 in 2021, then dropped by 4.86% to 6154839.0 in 2022, then tumbled by 74.59% to 10745694.0 in 2023, then jumped by 47.75% to 5614883.0 in 2024, then surged by 1782.34% to 94461181.0 in 2025.
- According to Business Quant data, Cash from Operations over the past three periods registered 94461181.0, 30856502.0, and 29991814.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | CorMedix | 645.20 Mn | 388.51 Mn | 77.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 94.46 Mn |
| Dec 31, 2025 | 94.46 Mn |
| Sep 30, 2025 | 30.86 Mn |
| Sep 30, 2025 | 30.86 Mn |
| Jun 30, 2025 | 29.99 Mn |
| Jun 30, 2025 | 29.99 Mn |
| Mar 31, 2025 | 19.74 Mn |
| Mar 31, 2025 | 19.74 Mn |
| Dec 31, 2024 | -5.61 Mn |
| Dec 31, 2024 | -5.61 Mn |
| Sep 30, 2024 | -13.65 Mn |
| Sep 30, 2024 | -13.65 Mn |
| Jun 30, 2024 | -14.04 Mn |
| Jun 30, 2024 | -14.04 Mn |
| Mar 31, 2024 | -17.31 Mn |
| Mar 31, 2024 | -17.31 Mn |
| Dec 31, 2023 | -10.75 Mn |
| Dec 31, 2023 | -10.75 Mn |
| Sep 30, 2023 | -8.70 Mn |
| Sep 30, 2023 | -8.70 Mn |